News stories about Ovid Therapeutc (NASDAQ:OVID) have been trending positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Ovid Therapeutc earned a news impact score of 0.27 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 48.1337635911226 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- Ovid Therapeutc (OVID) Releases Quarterly Earnings Results, Beats Expectations By $0.16 EPS (americanbankingnews.com)
- BRIEF-Ovid Therapeutics Q3 loss per share $0.38 (reuters.com)
- Ovid Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Progress (finance.yahoo.com)
- Can We Make Innovative Medicines Affordable? Part 2 (lifescienceleader.com)
- Ovid Therapeutics to Participate at the Stifel 2017 Healthcare Conference (finance.yahoo.com)
Ovid Therapeutc (NASDAQ:OVID) traded up $1.59 on Monday, reaching $9.03. The company had a trading volume of 101,300 shares, compared to its average volume of 74,297. Ovid Therapeutc has a one year low of $5.28 and a one year high of $15.93.
Ovid Therapeutc (NASDAQ:OVID) last issued its earnings results on Thursday, November 9th. The company reported ($0.38) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.54) by $0.16. equities analysts expect that Ovid Therapeutc will post -4.61 earnings per share for the current year.
Separately, Zacks Investment Research upgraded Ovid Therapeutc from a “sell” rating to a “hold” rating in a report on Tuesday, October 17th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Ovid Therapeutc presently has an average rating of “Buy” and an average price target of $23.50.
In other news, CEO Jeremy M. Levin bought 15,334 shares of the firm’s stock in a transaction on Friday, August 25th. The stock was acquired at an average cost of $7.15 per share, with a total value of $109,638.10. Following the transaction, the chief executive officer now directly owns 4,601,529 shares in the company, valued at approximately $32,900,932.35. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
About Ovid Therapeutc
Ovid Therapeutics Inc (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist.
Receive News & Ratings for Ovid Therapeutc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ovid Therapeutc and related companies with MarketBeat.com's FREE daily email newsletter.